Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers
Dan G Duda, Rakesh K Jain, Christopher G Willett, Dan G Duda, Rakesh K Jain, Christopher G Willett
Abstract
Although still in very early stages of clinical development, the combination of antiangiogenics with contemporary chemoradiotherapy regimens has emerged as a feasible and promising approach to many cancers. We review the rationale and the current understanding of antiangiogenics and their therapeutic potential in combination with chemoradiotherapy. Finally, we offer a perspective on future research directions aimed at making this complex therapeutic approach successful in the clinic.
Conflict of interest statement
Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
Although all authors completed the disclosure declaration, the following authors or their immediate family members indicated a financial interest. No conflict exists for drugs or devices used in a study if they are not being evaluated as part of the investigation. For a detailed description of the disclosure categories, or for more information about ASCO’s conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors.
Figures
Source: PubMed